Visceral adiposity important target for dyslipidemia management
MedWire News: Results of a Canadian study suggest that in order to "normalize" apolipoprotein B (apoB) levels after a healthy eating/physical activity program, viscerally obese and dyslipidemic men also need to normalize their visceral adiposity.
This makes visceral adipose tissue (VAT) an "important target for the management of dyslipidemia," comments the team in Atherosclerosis.
Few studies have investigated how VAT influences circulating apoB levels, say Jean-Pierre Després (Université Laval, Québec) and colleagues. They therefore examined the effect of a 1-year lifestyle modification program on plasma apoB levels in viscerally obese men and compared postintervention levels with those of a reference group of lean healthy men.
The intervention group included 107 men, aged between 30 and 65 years, who had an elevated waist circumference (≥90 cm) combined with the presence of atherogenic dyslipidemia (triglycerides ≥1.69 mmol/L [149.57 mg/dL] and/or high-density lipoprotein cholesterol <1.03 mmol/L [39.77 mg/dL]), and who participated in less than 30 minutes of physical activity per week.
The intervention consisted of a lifestyle-modification program in which individuals were offered personalized healthy eating and physical activity counseling.
The reference group included 60 non-obese (body mass index <25 kg/m2 and waist circumference <90 cm) normolipidemic healthy men, aged between 20 and 63 years.
After 1 year, the men in the lifestyle intervention had reduced their VAT by a significant 26%. The intervention also resulted in significant, but modest, improvements in fasting apoB levels, which were reduced by 3%.
When Després and co-investigators classified the intervention group into quartiles according to their VAT at 1-year, they found that only men in the lowest quartile of VAT (mean 844 cm3) appeared to have reduced their VAT level similar to that of the reference group (809 cm3).
In addition, these men were the only ones to show similar apoB levels to that of the reference group (0.98 vs 0.99 g/L).
These findings show that participants who achieved the lowest levels of VAT could normalize their apoB concentration, write the authors.
"Our study highlights the importance of monitoring body fat distribution patterns in the follow-up of patients undergoing lifestyle modification therapy to reduce cardiovascular risk," they conclude.
By Nikki Withers